Figure 2.

Agonist-induced structural rearrangements in the GB_1aR/G-protein/Ca_V2.2 channel complex. A, E between GB_1a^YFP/Ca_V2.2^CFP was reduced by baclofen (10 μm, left, n = 13–29, N = 4–6, ***p < 0.0001), but was increased by CGP54626 (1 μm, right, n = 14, N = 4, **p < 0.01). B, E between GB_1a^YFP/Gα_o^CFP was reduced by baclofen (10 μm, left, n = 12–17, N = 4, ***p < 0.0001), but was increased by GABA_BR antagonist CGP35348 (1 μm, right, n = 13–18, N = 4, ***p < 0.0001). C, E between GB_1a^CFP/Gβ₁^YFP was increased by baclofen (10 μm, left, n = 12–15, N = 4, ***p < 0.0001), but was decreased by GABA_BR antagonist CGP54626 (1 μm, right, n = 15, N = 4, ***p < 0.0001). D, E between Gβ₁^YFP/Ca_V2.2^CFP was increased by baclofen (10 μm, left, n = 14–27, N = 4–6, ***p < 0.0001), but was decreased by CGP54626 (1 μm, right, n = 14–17, N = 4–5, ***p < 0.0001). Error bars indicate SEM. E, Fluorescence intensity of pHluorin tagged to GB_1a does not change under miniature activity, by application of 10 μm baclofen and as function of stimulation frequency (10 and 100 Hz). Slope of linear fit is 1.04, 0.98, 1.01, and 0.99 for miniature activity, baclofen application, 10 and 100 Hz, respectively.